Dishman Carbogen Amcis: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
Dishman Carbogen Amcis is a | [[File:Dishman_Carbogen_Amcis_Ltd._Logo.png|thumb]]<br>Dishman Carbogen Amcis | ||
{{ | Dishman Carbogen Amcis is a global pharmaceutical company that specializes in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates. The company provides a range of services to the pharmaceutical industry, including custom synthesis, process development, and contract manufacturing. | ||
==History== | |||
Dishman Carbogen Amcis was established through the merger of Dishman Pharmaceuticals and Chemicals Limited and Carbogen Amcis AG. Dishman Pharmaceuticals was founded in 1983 in India, while Carbogen Amcis AG was established in Switzerland. The merger aimed to combine the strengths of both companies to offer comprehensive solutions to the pharmaceutical industry. | |||
==Operations== | |||
The company operates through several facilities located in India, Switzerland, the United Kingdom, and China. These facilities are equipped with state-of-the-art technology to support the development and production of complex chemical compounds. | |||
===India=== | |||
In India, Dishman Carbogen Amcis has multiple manufacturing sites that focus on the production of APIs and intermediates. These sites are compliant with international regulatory standards, including the US FDA and the European Medicines Agency (EMA). | |||
===Switzerland=== | |||
The Swiss operations are centered around Carbogen Amcis AG, which provides high-potency API development and manufacturing services. The Swiss facilities are known for their expertise in handling highly potent compounds and cytotoxic substances. | |||
===United Kingdom=== | |||
In the UK, the company operates a facility that specializes in the development of niche APIs and complex chemical synthesis. | |||
===China=== | |||
The Chinese operations focus on the production of intermediates and APIs for the local and international markets. The facility in China is designed to meet the growing demand for pharmaceutical products in the Asia-Pacific region. | |||
==Services== | |||
Dishman Carbogen Amcis offers a wide range of services to its clients, including: | |||
* '''[[Custom Synthesis]]''': Tailored chemical synthesis services to meet specific client requirements. | |||
* '''[[Process Development]]''': Development of efficient and scalable chemical processes for API production. | |||
* '''[[Contract Manufacturing]]''': Large-scale manufacturing of APIs and intermediates under contract. | |||
* '''[[Analytical Services]]''': Comprehensive analytical testing and validation services to ensure product quality and compliance. | |||
==Research and Development== | |||
The company invests significantly in research and development to innovate and improve its product offerings. The R&D teams work on developing new chemical entities and optimizing existing processes to enhance efficiency and reduce costs. | |||
==Related Pages== | |||
* [[Active Pharmaceutical Ingredient]] | |||
* [[Contract Manufacturing Organization]] | |||
* [[Pharmaceutical Industry]] | |||
* [[Chemical Synthesis]] | |||
{{Pharmaceutical Company}} | |||
[[Category:Pharmaceutical companies]] | |||
[[Category:Companies established in 1983]] | |||
[[Category:Companies based in India]] | |||
[[Category:Companies based in Switzerland]] | |||
Latest revision as of 04:30, 9 January 2025
Dishman Carbogen Amcis
Dishman Carbogen Amcis is a global pharmaceutical company that specializes in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates. The company provides a range of services to the pharmaceutical industry, including custom synthesis, process development, and contract manufacturing.
History[edit]
Dishman Carbogen Amcis was established through the merger of Dishman Pharmaceuticals and Chemicals Limited and Carbogen Amcis AG. Dishman Pharmaceuticals was founded in 1983 in India, while Carbogen Amcis AG was established in Switzerland. The merger aimed to combine the strengths of both companies to offer comprehensive solutions to the pharmaceutical industry.
Operations[edit]
The company operates through several facilities located in India, Switzerland, the United Kingdom, and China. These facilities are equipped with state-of-the-art technology to support the development and production of complex chemical compounds.
India[edit]
In India, Dishman Carbogen Amcis has multiple manufacturing sites that focus on the production of APIs and intermediates. These sites are compliant with international regulatory standards, including the US FDA and the European Medicines Agency (EMA).
Switzerland[edit]
The Swiss operations are centered around Carbogen Amcis AG, which provides high-potency API development and manufacturing services. The Swiss facilities are known for their expertise in handling highly potent compounds and cytotoxic substances.
United Kingdom[edit]
In the UK, the company operates a facility that specializes in the development of niche APIs and complex chemical synthesis.
China[edit]
The Chinese operations focus on the production of intermediates and APIs for the local and international markets. The facility in China is designed to meet the growing demand for pharmaceutical products in the Asia-Pacific region.
Services[edit]
Dishman Carbogen Amcis offers a wide range of services to its clients, including:
- Custom Synthesis: Tailored chemical synthesis services to meet specific client requirements.
- Process Development: Development of efficient and scalable chemical processes for API production.
- Contract Manufacturing: Large-scale manufacturing of APIs and intermediates under contract.
- Analytical Services: Comprehensive analytical testing and validation services to ensure product quality and compliance.
Research and Development[edit]
The company invests significantly in research and development to innovate and improve its product offerings. The R&D teams work on developing new chemical entities and optimizing existing processes to enhance efficiency and reduce costs.
